Navigation Links
HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007
Date:2/25/2008

and facilities held for

sale at end of year (0.4) (14.4)

Cash and cash equivalents at end of year $19.8 $27.1

Operating activities. Net cash provided by operating activities increased by $360.5 million from 2006 to 2007. This increase resulted from higher net operating revenues and lower operating expenses year over year. Specifically, we experienced a $109.8 million reduction in professional fees-accounting, tax, and legal from 2006 to 2007. In addition, we received a $440 million federal income tax recovery in October 2007. Net cash provided by operating activities in 2007 and 2006 also included payments of approximately $171.4 million and $132.8 million, respectively, related to government, class action, and related settlements.

Investing activities. The increase in net cash provided by investing activities from 2006 to 2007 was due to the cash proceeds received from the divestitures of our surgery centers, outpatient, and diagnostic divisions during 2007.

Financing activities. The increase in net cash used in financing activities was due to the use of the net cash proceeds from the divestitures of our surgery centers, outpatient, and diagnostic divisions, as well as the majority of our federal income tax recovery, to reduce debt outstanding under our Credit Agreement during 2007. During 2007, we made approximately $1.3 billion of net debt payments, while during 2006, we made approximately $246.3 million of net debt payments. Financing activities for 2006 also included approximately $387.4 million of net proceeds from the issuance of convertible perpetual preferred stock.

HealthSouth Corporation and Subsidiaries

Supplemental Non-GAAP Disclosures

Adjusted Consolidated EBITDA

Three Months Ended Year Ended


'/>"/>

SOURCE HealthSouth Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
2. HealthSouth Issues Statement on Medicare Bill and 75% Rule
3. HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government
4. HealthSouth and Physicians Pay $14.9 Million to Settle Health Care Fraud Claims
5. HealthSouth Announces Date of Third Quarter Earnings Conference Call
6. HealthSouth Corporation Appoints New Member to Board of Directors
7. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
8. NHP Reports Fourth Quarter and Full Year 2007 Earnings
9. High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter
10. Clarity for Consumers on Botox Complication and Death Reports
11. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
(Date:2/27/2015)... Legislation passed today by the House ... to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA), introduced by ... (R-TX) and Ranking Member Jim McDermott (D-WA), recognizes ... epidemic and implement the right policies, said the ...
(Date:2/27/2015)... Winter is here, and with it comes harsh ... snow and ice can be harmful on a dog’s paws. ... Puppy Store is ready to help pet owners know what ... the winter time. , Ice melts can lead to several ... Ingestion of ice melt products may cause depression, loss of ...
(Date:2/27/2015)... February 27, 2015 The Dawn Greene Hospice, ... Manning Walsh Home (MMW) on the Upper East Side, was ... of New York, His Eminence Timothy Michael Cardinal Dolan. , ... Board of Directors and a member of the ArchCare Board ... Sean William O’Brien, O.Carm, executive director of MMW, and Christina ...
(Date:2/27/2015)... 2015 FACE Skincare~Medical~Wellness, a multiaward-winning ... a unique combination to take fifteen years off ... is a new treatment introduced that is the ... indicated to improve lines and wrinkles on the ... who suffers from the stubborn vertical lines between ...
Breaking Medicine News(10 mins):Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:Face Skincare Announces New Combination Therapy 2
... Philadelphians are expected to join the Lupus WHAT: Foundation of America for ... information and refreshments to support the need ... and information about signs and symptoms, diagnosis and tips to ... available at no charge to everyone., ...
... with secure transmission of patient data ... from hospital EMR to web-based PHR, ... (ICW), a global leader in eHealth technology,solutions and Memorial Hospital ... phase of Project Anchor, an initiative led by,Dr. Charles Eaton, ...
... and Optimize Reconstruction Surgery, TORONTO, May 8 ... of real-time imaging and image guidance systems for,use ... surgeons at Duke,University Hospital in Durham, North Carolina ... reconstructive surgical procedures. Since,beginning to use SPY near ...
... May 8 Biopure Corporation,(Nasdaq: BPUR ) ... has received new funding of approximately $3.4 million ... being granted,through the Department of Defense for a ... of Polytrauma Combat Casualties,with Brain Injury and Concomitant ...
... Scientific,Corporation (NYSE: BSX ) today announced U.S. ... family of pacemakers. ALTRUA is Boston,Scientific,s most advanced ... size and battery longevity. It is the first ... which the,heart beats too slowly -- usually less ...
... IDMI ) today reported financial results for the ... consolidated,results of IDM Pharma, Inc. and its subsidiary, IDM ... $2.4 million, and net loss was,$12.1 million or $0.48 ... non-cash charges of $4.7 million related to the increase ...
Cached Medicine News:Health News:5th Annual World Lupus Day Philadelphians Take Part In a Global Rally of Support 2Health News:InterComponentWare Inc. and Memorial Hospital of Rhode Island Celebrate Milestone 2Health News:InterComponentWare Inc. and Memorial Hospital of Rhode Island Celebrate Milestone 3Health News:InterComponentWare Inc. and Memorial Hospital of Rhode Island Celebrate Milestone 4Health News:Leading Plastic Surgeons at Duke Adopt SPY 2Health News:Leading Plastic Surgeons at Duke Adopt SPY 3Health News:Leading Plastic Surgeons at Duke Adopt SPY 4Health News:U.S. Navy Receives Funding for Further Development of Hemopure(R) 2Health News:U.S. Navy Receives Funding for Further Development of Hemopure(R) 3Health News:Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers 2Health News:Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers 3Health News:Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers 4Health News:IDM Pharma Reports First Quarter Financial Results 2Health News:IDM Pharma Reports First Quarter Financial Results 3Health News:IDM Pharma Reports First Quarter Financial Results 4Health News:IDM Pharma Reports First Quarter Financial Results 5Health News:IDM Pharma Reports First Quarter Financial Results 6Health News:IDM Pharma Reports First Quarter Financial Results 7Health News:IDM Pharma Reports First Quarter Financial Results 8
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... CARLSBAD, Calif., Feb. 27, 2015 Isis Pharmaceuticals, ... significantly outperformed both its pro forma net operating loss ... in a strong financial position.  Isis, significantly improved financial ... than $230 million in payments the Company received from ... for 2014 was a nearly 60% improvement over its ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... trial show those treated with,Prexige experienced significantly smaller ... Many patients with osteoarthritis also have high blood,pressure; ... risk[2],[3] , * Prexige approved in more than ... use in osteoarthritis patients , BASEL, Switzerland, June ...
... an AI Over Tamoxifen in,a Single Trial ... of the entire,population of a single trial has ... significantly improved by switching from,tamoxifen to anastrozole (Arimidex). ... published online in The,Journal of Clinical Oncology, confirms ...
Cached Medicine Technology:Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 6Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 2Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 3Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 4Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 5
... a broad selection of tip ... wide variety of ophthalmic procedures. ... packaged sterile, complete with a ... in the "off " position ...
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... provide a broad selection of tip ... variety of ophthalmic procedures. Each single ... with a safety cap to lock ... when not in use, and carries ...
Medicine Products: